Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1
will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will
consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing
schedule is IV every 3 to 4 weeks.